PURPOSE: Kinetic visual field testing is used to monitor disease course in retinal dystrophy clinical care and treatment response in treatment trials, which are increasingly recruiting children. This study investigates Goldmann visual field (GVF) changes in young children with mutation-proven retinal dystrophies as they age and with progression of the retinal degeneration. METHODS: Retrospective review of children ≤ 17 years old with a mutation-proven retinal dystrophy. Objective clinical disease activity was assessed by a retinal degeneration specialist masked to GVF results. Digital quantification of GVF area was performed. RESULTS: Twenty-nine children (58 eyes), ages 5-16, were identified. GVF area increased with age despite progression in 20 children and clinical stability in nine children. Mean ± standard error increase in GVF area/year was 333 ± 130 mm2 (I4e, p = 0.012), 720 ± 155 mm2 (III4e, p < 0.001), and 759 ± 167 mm2 (IV4e, p < 0.001), with greater increases at earlier ages. Repeatability coefficients were 7381 mm2 (I4e), 9379 mm2 (III4e), and 10346 mm2 (IV4e), indicating a large variability. At 2.5 years after the baseline GVF the area increased ≥ 20%, the criterion for positive treatment outcome defined in recent published therapeutic trials, in 38% (I4e), 34% (III4e), and 33% (IV4e) of eyes. CONCLUSION: In a substantial proportion of children with mutation-proven retinal dystrophies, there is a significant increase in GVF area with age, particularly those < 12 years, despite progression or stability of disease. These findings suggest that change in GVF area in children with retinal dystrophies can be an unreliable measure of response to treatment and on which to base appropriate counseling about visual impairment.
PURPOSE: Kinetic visual field testing is used to monitor disease course in retinal dystrophy clinical care and treatment response in treatment trials, which are increasingly recruiting children. This study investigates Goldmann visual field (GVF) changes in young children with mutation-proven retinal dystrophies as they age and with progression of the retinal degeneration. METHODS: Retrospective review of children ≤ 17 years old with a mutation-proven retinal dystrophy. Objective clinical disease activity was assessed by a retinal degeneration specialist masked to GVF results. Digital quantification of GVF area was performed. RESULTS: Twenty-nine children (58 eyes), ages 5-16, were identified. GVF area increased with age despite progression in 20 children and clinical stability in nine children. Mean ± standard error increase in GVF area/year was 333 ± 130 mm2 (I4e, p = 0.012), 720 ± 155 mm2 (III4e, p < 0.001), and 759 ± 167 mm2 (IV4e, p < 0.001), with greater increases at earlier ages. Repeatability coefficients were 7381 mm2 (I4e), 9379 mm2 (III4e), and 10346 mm2 (IV4e), indicating a large variability. At 2.5 years after the baseline GVF the area increased ≥ 20%, the criterion for positive treatment outcome defined in recent published therapeutic trials, in 38% (I4e), 34% (III4e), and 33% (IV4e) of eyes. CONCLUSION: In a substantial proportion of children with mutation-proven retinal dystrophies, there is a significant increase in GVF area with age, particularly those < 12 years, despite progression or stability of disease. These findings suggest that change in GVF area in children with retinal dystrophies can be an unreliable measure of response to treatment and on which to base appropriate counseling about visual impairment.
Authors: Robert K Koenekoop; Ruifang Sui; Juliana Sallum; L Ingeborgh van den Born; Radwan Ajlan; Ayesha Khan; Anneke I den Hollander; Frans P M Cremers; Janine D Mendola; Ava K Bittner; Gislin Dagnelie; Ronald A Schuchard; David A Saperstein Journal: Lancet Date: 2014-07-13 Impact factor: 79.321
Authors: Callie Deng; Peter Y Zhao; Kari Branham; Dana Schlegel; Abigail T Fahim; Thiran K Jayasundera; Naheed Khan; Cagri G Besirli Journal: Graefes Arch Clin Exp Ophthalmol Date: 2022-01-10 Impact factor: 3.535
Authors: Benjamin Otte; Chris Andrews; Gabrielle Lacy; Kari Branham; David C Musch; Kanishka T Jayasundera Journal: Ophthalmic Genet Date: 2021-01-06 Impact factor: 1.803
Authors: Jacob Jeries Abou-Hanna; Chris A Andrews; Naheed W Khan; David C Musch; K Thiran Jayasundera Journal: Ophthalmic Genet Date: 2021-03-17 Impact factor: 1.274
Authors: Malena Daich Varela; Ehsan Ullah; Sairah Yousaf; Brian P Brooks; Robert B Hufnagel; Laryssa A Huryn Journal: Invest Ophthalmol Vis Sci Date: 2020-10-01 Impact factor: 4.799